Cereblon E3 ubiquitin-ligase

Assets acting on this target.

Class
small molecule
Notes
original target text: Cereblon E3 ubiquitin-ligase modulator

Cereblon is a substrate receptor within a multi-subunit ubiquitin ligase complex that normally tags specific proteins for the proteasome, the cell's disposal machinery, marking them for destruction. Certain small molecules, historically classed as immunomodulatory drugs and now including newer cereblon E3 ligase modulators, bind cereblon and change which proteins it recognizes. Rather than blocking cereblon's activity, these molecular-glue compounds redirect it to bind and destroy new target proteins, called neosubstrates, that it would not normally engage. In blood cancers such as multiple myeloma, key neosubstrates are transcription factors that cancer cells depend on for survival; their removal triggers cell death. The same drugs also alter immune cell signaling, enhancing anti-tumor immune responses, which broadens their use beyond direct cancer cell killing. Because a single agent can be engineered to favor particular neosubstrate profiles, chemists have produced successive generations of these modulators seeking greater potency, selectivity, or breadth of protein degradation. This mechanism matters across hematologic malignancies and is being explored in autoimmune disease, since selective degradation of immune transcription factors can also dampen pathological immune activity. It represents one of the clearest examples of targeted protein degradation using small molecules rather than direct enzyme inhibition.

By indication

Related mechanisms

Cereblon E3 ubiquitin-ligase drugs compared

7 drugs, stage by indication
7 drugs acting on Cereblon E3 ubiquitin-ligase: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
IberdomideZenbexusBristol-Myers Squibbsmall molecule (CELMoD / cereblon E3 ligase modulator)ApprovedApproved in Multiple Myeloma
LenalidomideBristol-Myers Squibb, Celgene Corporationsmall molecule (IMiD / cereblon modulator)ApprovedApproved in Follicular Lymphoma; Approved in Mantle Cell Lymphoma; Approved in Multiple Myeloma; Approved in Myelodysplastic Syndromes
ThalidomideBristol-Myers Squibbsmall molecule (IMiD / cereblon modulator, first-generation)ApprovedApproved in Multiple Myeloma
MezigdomideBristol-Myers Squibbsmall moleculePhase 3Phase 3 in Multiple Myeloma
CemsidomideC4 Therapeutics, Inc.small molecule (targeted protein degrader / cereblon E3 ligase modulator)Phase 2Phase 2 in Multiple Myeloma
ICP-490Beijing InnoCare Pharma Tech Co.small molecule (cereblon-based molecular glue / IKZF1-3 degrader, CELMoD)Phase 1/2Phase 1/2 in Multiple Myeloma
TQB3820Sino Biopharmaceuticalsmall moleculePhase 1Not recorded

← all mechanisms